STAT3 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2.
HeLa
Human
Cervix
Sanger Sequencing, Western blot
Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2.
1110034C02Rik, ADMIO, APRF, AW109958, Acute-phase response factor, DNA binding protein APRF, FLJ20882, HIES, MGC16063, STAT3_HUMAN, Signal transducer and activator of transcription 3, Signal transducer and activator of transcription 3 (acute phase response factor)
STAT3 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2.
HeLa
Human
Cervix
Sanger Sequencing, Western blot
Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2.
Adenocarcinoma
STAT3
Knockout
CRISPR technology
Sanger Sequencing, Western blot
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
EU: 2 US: 2
Adherent
Female
Ambient - Can Ship with Ice
-20°C
-20°C
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
This supplementary information is collated from multiple sources and compiled automatically.
Signal Transducer and Activator of Transcription 3 (STAT3) also called p-stat3 or phospho-STAT3 is a critical transcription factor involved in various cellular processes. The molecular weight of STAT3 is approximately 92 kDa. This protein is expressed broadly across many tissues and cell types. Mechanically upon cytokine or growth factor stimulation STAT3 undergoes phosphorylation resulting in dimerization. This phosphorylated form often referred to as phospho-Stat3 or p-STAT3 translocates to the nucleus where it binds specific DNA sequences to modulate gene transcription.
STAT3 is an important player in regulating cell growth and apoptosis. It functions not only as a transcription factor but also as part of a larger protein complex that operates within the cell nucleus to influence gene expression. This multifaceted role enables STAT3 to control the expression of genes related to cell proliferation survival and differentiation impacting various biological processes. These functions highlight its importance in tissue homeostasis and response to extracellular signals.
STAT3 is actively involved in the JAK-STAT signaling pathway a principal route for many cytokines and growth factors and the MAPK pathway. STAT3 interacts with proteins such as JAK kinases which phosphorylate Stat3 and initiate the STAT3 signaling cascade. Additionally it closely associates with the protein Raf1 in the MAPK pathway linking external signals to transcriptional responses. These pathways play a significant role in immune response inflammation and growth signaling.
Researchers have implicated STAT3 in cancer and autoimmune diseases. Persistent activation of STAT3 is often observed in various cancers including breast and lung cancer promoting oncogenesis through altered gene expression. Additionally abnormal STAT3 signaling is associated with autoimmune conditions such as rheumatoid arthritis. The interplay between STAT3 and proteins like IL-6 in these diseases highlights its potential as a therapeutic target for intervention.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Blocking and diluting buffer and concentration: Intercept® (TBS) Blocking Buffer diluted with an equal volume of 0.1% TBS.
Lane 1: Wild-type HeLa (human cervix adenocarcinoma epithelial cell) serum starved overnight, then treated with 50 ng/ml IFN alpha for 30 minutes, whole cell lysate (20μg)
Lane 2:STAT3 knockout HeLa serum starved overnight, then treated with 50 ng/ml IFN alpha for 30 minutes, whole cell lysate (20μg)
Lane 3: Jurkat (human t cell leukemia cell line from peripheral blood) treated with 50 ng/ml IFN alpha for 30 minutes, whole cell lysate (20μg)
Lane 4:HepG2 (human hepatocellar carcinoma epithelial cell) serum starved overnight, then treated with 100 ng/ml IL-6 for 30 minutes, whole cell lysate (20μg)
Lanes 1-4: Merged signal (red and green). Green - Anti-STAT3 (phospho Y705) antibody [EPR23968-52] ab267373 observed at 88 kDa. Red - loading control Anti-GAPDH antibody [6C5] - Loading Control ab8245 (Mouse monoclonal [6C5] to GAPDH) observed at 36 kDa.
Lanes 1-2: Anti-STAT3 (phospho Y705) antibody [EPR23968-52] ab267373 Anti-STAT3 (phospho Y705) antibody [EPR23968-52] was shown to specifically react with STAT3 in wild-type serum starved and then IFN alpha treated HeLa cells. Loss of signal was observed when serum starved and then IFN alpha treated knockout cell line Human STAT3 knockout HeLa cell line ab255436 (knockout cell lysate ab263797) was used. Wild-type and STAT3 knockout samples were subjected to SDS-PAGE. Anti-STAT3 (phospho Y705) antibody [EPR23968-52] ab267373 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated at 4°C overnight at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 10000 dilution for 1 hour at room temperature before imaging.
Lysates loaded onto lanes 3-4 were made freshly and used in WB immediately to minimize protein degradation.
All lanes: Western blot - Anti-STAT3 (phospho Y705) antibody [EPR23968-52] (Anti-STAT3 (phospho Y705) antibody [EPR23968-52] ab267373) at 1/1000 dilution
Lane 1: Wild-type HeLa (human cervix adenocarcinoma epithelial cell) serum starved overnight, then treated with 50 ng/ml IFN alpha for 30 minutes, whole cell lysate at 20 µg
Lane 2: STAT3 knockout HeLa serum starved overnight, then treated with 50 ng/ml IFN alpha for 30 minutes, whole cell lysate at 20 µg
Lane 3: Jurkat (human t cell leukemia cell line from peripheral blood) treated with 50 ng/ml IFN alpha for 30 minutes, whole cell lysate at 20 µg
Lane 4: HepG2 (human hepatocellar carcinoma epithelial cell) serum starved overnight, then treated with 100 ng/ml IL-6 for 30 minutes, whole cell lysate at 20 µg
All lanes: Goat Anti-Rabbit IgG H&L (IRDye® 800CW) (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat Anti-Mouse IgG H&L (IRDye® 680RD) (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) at 1/10000 dilution
Predicted band size: 88 kDa
Observed band size: 88 kDa
Lane 1: Wild-type HeLa cell lysate (20µg)
Lane 2: STAT3 knockout HeLa cell lysate (20µg)
Lanes 1- 2: Merged signal (red and green). Green - Anti-STAT3 antibody [EPR361] ab109085 observed at 92 kDa. Red - loading control Anti-GAPDH antibody [6C5] - Loading Control ab8245 observed at 37 kDa.
Anti-STAT3 antibody [EPR361] ab109085 Recombinant Anti-STAT3 antibody [EPR361] was shown to specifically react with STAT3 in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line Human STAT3 knockout HeLa cell line ab255436 (knockout cell lysate ab263797) was used. Wild-type and STAT3 knockout samples were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. Anti-STAT3 antibody [EPR361] ab109085 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-STAT3 antibody [EPR361] (Anti-STAT3 antibody [EPR361] ab109085) at 1/1000 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: STAT3 knockout HeLa cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 88 kDa
Observed band size: 92 kDa
Lane 1: Wild-type HeLa cell lysate (20µg)
Lane 2: STAT3 knockout HeLa cell lysate (20µg)
Lanes 1- 2: Merged signal (red and green). Green - Anti-STAT3 antibody [EPR787Y] ab68153 observed at 92 kDa. Red - loading control Anti-GAPDH antibody [6C5] - Loading Control ab8245 observed at 37 kDa.
Anti-STAT3 antibody [EPR787Y] ab68153 Recombinant Anti-STAT3 antibody [EPR787Y] was shown to specifically react with STAT3 in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line Human STAT3 knockout HeLa cell line ab255436 (knockout cell lysate ab263797) was used. Wild-type and STAT3 knockout samples were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. Anti-STAT3 antibody [EPR787Y] ab68153 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-STAT3 antibody [EPR787Y] (Anti-STAT3 antibody [EPR787Y] ab68153) at 1/1000 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: STAT3 knockout HeLa cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 88 kDa
Observed band size: 92 kDa
Homozygous: 1 bp deletion in exon2
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com